FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1842-1845 December 9, 1999 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Sandler, A. D. PubMed Citation

In this issue of the Journal, Sandler and colleagues report the negative results of a double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in children with autism or pervasive developmental disorder.¹ Autistic disorder is a serious neuropsychiatric disorder with onset in the first years of life that is characterized by delayed and deviant social and communication skills, associated with various forms of unusual behavior (e.g., repetitive behavior and unusual responses to the environment).² The term pervasive developmental disorder not otherwise specified refers to a condition with symptoms suggestive of autism but that does not meet the . . . [Full Text of this Article]

References

Related Letters:

Secretin Treatment for Autism
Horvath K., Rimland B., Herlihy W. C., Said S. I., Bodanszky M., Sandler A., Volkmar F.
Extract | Full Text  
N Engl J Med 2000; 342:1216-1218, Apr 20, 2000. Correspondence

This article has been cited by other articles:

• Volkmar, F. R. (2009). Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior. Arch Gen Psychiatry 66: 581-582 [Full Text]  
• Burman, W. J., Reves, R. R., Cohn, D. L., Schooley, R. T. (2001). Breaking the Camel's Back: Multicenter Clinical Trials and Local Institutional Review Boards. ANN INTERN MED 134: 152-157 [Abstract] [Full Text]  
• Gringras, P. (2000). Practical Paediatric Psychopharmacological Prescribing in Autism: The Potential and the Pitfalls. Autism 4: 229-247 [Abstract]  
• Siegel, B. (2000). Synthetic human secretin did not improve symptoms or communication skills in children with autistic disorders. Evid. Based Ment. Health 3: 52-52 [Full Text]  
• Horvath, K., Rimland, B., Herlihy, W. C., Said, S. I., Bodanszky, M., Sandler, A., Volkmar, F. (2000). Secretin Treatment for Autism. NEJM 342: 1216-1218 [Full Text]